Chai Discovery is a technology company.
Chai Discovery focuses on drug-like antibody design using artificial intelligence, aiming to create better molecules with atomic precision for real therapeutics.
Chai Discovery has raised $100.0M across 2 funding rounds.
Chai Discovery has raised $100.0M in total across 2 funding rounds.
Chai Discovery has raised $100.0M in total across 2 funding rounds.
Chai Discovery's investors include 8VC, Alkeon Capital, C2 Investment, Gaingels, Indeed.com, Innovation Endeavors, LGF, Menlo Ventures, Otherwise Fund, Paradigm, Stellar Capital, Thrive Capital.
Chai Discovery is a biotech startup founded in 2024 that builds AI foundation models to predict and reprogram interactions between biochemical molecules, enabling de novo antibody design and drug-like molecule creation.[1][2][5] It serves life sciences researchers and drug developers by tackling hard-to-drug targets, with products like Chai-1 and the advanced Chai-2 model, which improve success rates in designing custom antibodies from scratch.[2][5] The company has shown explosive growth, raising $30M in seed funding, followed by a $70M Series A, and a $130M Series B in December 2025 at a $1.3B valuation, totaling over $225M from top investors including OpenAI, Thrive Capital, General Catalyst, and Menlo Ventures.[1][2][4]
This momentum positions Chai Discovery as a leader in AI-driven drug discovery, accelerating the shift from traditional trial-and-error methods to precise, computational design of therapeutics.[2][5]
Chai Discovery was founded in 2024 in New York by Joshua Meier (CEO and co-founder, with prior experience in machine learning at Facebook and OpenAI) and Jack Dent (co-founder).[2][3] The idea emerged from Meier's expertise in AI research, aiming to create foundation models specifically tuned for biochemistry to predict molecular interactions and enable reprogramming for drug development.[1][2] Early traction came swiftly: within a year, the company launched Chai-1, secured $30M in seed funding from high-profile backers like OpenAI and Thrive Capital, and emerged from Neo's talent program, which has nurtured successes like Cognition and Pika Labs.[1][2] Pivotal moments include the $70M Series A in August 2025 led by Menlo Ventures and the recent $130M Series B, validating its rapid progress in de novo antibody design.[2][4]
Chai Discovery rides the AI-for-drug-discovery wave, where foundation models cut development timelines from years to months by simulating molecular behaviors at scale.[2] Timing is ideal amid surging investments in biotech AI—exemplified by peers like insitro—and post-ChatGPT AI hype extending to science, with Chai's OpenAI ties amplifying credibility.[1][2][3] Market forces favoring it include exploding demand for precision medicine, antibody therapeutics (a $200B+ market), and compute advancements enabling complex simulations.[2][5] It influences the ecosystem by democratizing access to advanced models (via "Get Access" offerings), inspiring AI-biotech hybrids, and proving Neo's talent pipeline yields unicorns like itself.[1][5]
Chai Discovery's trajectory—from 2024 seed to $1.3B valuation in 2025—signals it's poised to redefine antibody and drug design, with Chai-2 edging toward clinical-ready molecules.[2][5] Next steps likely include partnerships with pharma giants for real-world trials, model releases like Chai-3, and potential IPO as AI-biotech matures.[2] Trends like multimodal AI (integrating structure, sequence, function) and regulatory nods for AI-designed drugs will propel it, evolving its role from pioneer to infrastructure provider for the life sciences revolution—echoing its mission to engineer better molecules at atomic precision.[5]
Chai Discovery has raised $100.0M across 2 funding rounds. Most recently, it raised $70.0M Series A in August 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2025 | $70.0M Series A | 8VC, Alkeon Capital, C2 Investment, Gaingels, Indeed.com, Innovation Endeavors, LGF, Menlo Ventures, Otherwise Fund, Paradigm, Stellar Capital, Thrive Capital, Y Combinator, Elad Gil, John Collison, Konstantin von Unger, Patrick Collison | |
| Sep 1, 2024 | $30.0M Seed | 50 Partners, NEO, Outrun Ventures, Stellar Capital, Stellation Capital, Vibe Capital, Y Combinator, Kelvin Beachum Jr., Kevin Weil, Ron Pragides, Thibaud Elziere, William Levy |